Navigation Links
Omeros Corporation Reports First Quarter 2011 Financial Results
Date:5/10/2011

SEATTLE, May 10, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2011.

Financial ResultsTotal operating expenses for the three months ended March 31, 2011 were $7.7 million compared to $6.8 million for the same periods in 2010. The increase in operating expense was primarily due to increased clinical trial activities and additional employee costs. For the three months ended March 31, 2011, Omeros reported a net loss of $6.5 million, or $0.30 per share. During the same period in 2010, Omeros reported a net loss of $6.7 million, or $0.31 per share. At March 31, 2011, Omeros had cash, cash equivalents and short-term investments of $43.6 million.  

"The first quarter included several significant events for Omeros, most notably the announcement that our OMS103HP Phase 3 ACL program did not meet its prespecified primary endpoints," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While this setback delays OMS103HP's commercialization opportunity, the meniscectomy indication for the drug remains viable and, based on strong Phase 2 data, Phase 3 preparations are underway. We also recently reported positive results from our OMS302 Phase 2b, full-factorial OMS302 cataract trial and are submitting a request to the FDA for an end-of-Phase-2 meeting. We are evaluating our multiple options and will soon finalize our clinical plans for the remainder of 2011."

Recent Highlights

  • Announced that Omeros obtained an exclusive license to novel antifibrinolytic agents for the control of surgical and traumatic bleeding.  Research on these agents was published in the February 11,
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
    2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
    3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
    4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
    5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
    6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
    7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
    8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
    9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
    10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
    11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
    (Date:9/30/2014)... 2014 A study using a relatively new ... look at the composition of carotid artery disease and ... treat the disease, a leading cause of stroke. ... between September 2010 and May 2012, was featured in ... the American College of Cardiology (JACC) Cardiovascular Interventions. ...
    (Date:9/30/2014)... BEACH, Calif. , Sept. 30, 2014 /PRNewswire-USNewswire/ ... accreditation of the American Association of Tissue Banks ... Cook , Chief Executive Officer. Accreditation ... inspection by a specially trained AATB inspector.  It ... administrative performance within the facility meets or exceeds ...
    Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2
    ... Oct. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ) ... researching, developing, manufacturing and marketing,biopharmaceutical products, today announced the ... October 12, 2009. , At ... and Mr.,Moujia Qi to serve as members of the ...
    ... used to treat high blood pressure appear to be effective ... stable ischemic heart disease, according to a new comparative effectiveness ... A version of the analysis was posted in the ... Medicine . , Treatment featuring the two medications -- inhibitors ...
    Cached Medicine Technology:High Blood Pressure Medicines Show Promise For Treating Heart Disease 2High Blood Pressure Medicines Show Promise For Treating Heart Disease 3
    (Date:9/30/2014)... 2014 (HealthDay News) -- Sleep apnea is a potential health ... to a possible culprit behind the disorder: a "fat" tongue. ... deposits are increased in the tongue of obese patients with ... of the Sleep Center at the University of Pennsylvania Medical ... which will publish the findings Oct. 1. Sleep apnea ...
    (Date:9/30/2014)... SILVERTHORNE, CO September 30, 2014 Keystone Symposia ... and the first in its 2014-15 Global Health Series ... at the Sheraton Seattle Hotel immediately following the ... grantees. The four-day conference is part of the Keystone ... Melinda Gates Foundation, which has also funded travel awards ...
    (Date:9/30/2014)... (PRWEB) September 30, 2014 Dynamic ... have hampered growth in the Bread Production industry ... caused consumers to moderate their consumption of a ... for premium varieties shrunk the market for white ... operators proactively responded by introducing more nutritious products ...
    (Date:9/30/2014)... Research by UC Irvine immunologists reveals new information ... a vital process that determines how the body,s ability ... of Nature Immunology , neurology professor Dr. Michael ... Immunology colleagues describe a critical mechanism underlying how T ... , A T cell is a type of blood ...
    (Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
    Breaking Medicine News(10 mins):Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2
    ... One-fourth of overweight children may have sleep problems that ... ,Research published in the November issue of Obesity ... children tested positive for sleep-disordered breathing, including telltale snoring. ... after-school physical activity such as jumping rope, basketball and ...
    ... a dearth of specialists, which was confirmed by the Hospital ... the hospital will have to put up with the shortfall ... services is currently on leave. The hospital is in the ... , ,The medical board is also ...
    ... and cynical exploitation” by the alternative medicines industry, argues a ... estimated that up to 80% of all patients with cancer ... help treat their cancer, writes Jonathan Waxman, Professor of Oncology ... the use of many of these approaches is obtuse – ...
    ... study on schizophrenic patients has come up with a finding ... anti-psychotic drugs. // ,The study was conducted upon ... the treatment they were getting was ineffective. They were then ... on new. Experienced doctors decided which type of anti–psychotic drug ...
    ... examination of 4 cases of botulism following cosmetic injections ... highly concentrated, //unlicensed preparation that resulted in toxin levels ... according to a report. ,Botulism is a rare ... bacterium Clostridium botulinum and toxin-producing strains of Clostridium baratii ...
    ... in on cardiac master cells that could develop into ... groups of researchers who have been putting their independent ... teams from Massachusetts General Hospital have recognized a variety ... this could develop into cardiac muscle, endothelial cells or ...
    Cached Medicine News:Health News:Sleep Problems in Overweight Children Appear Fairly Common 2Health News:Sleep Problems in Overweight Children Appear Fairly Common 3Health News:Protect Patients from Exploitation by Alternative Medicines Industry, Says Expert 2Health News:Old Anti-psychotic Drugs Are Equally Good 2Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 2Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: